Literature DB >> 30377272

CFI-400945 is not a selective cellular PLK4 inhibitor.

Karen Oegema1, Robert L Davis2, Pablo Lara-Gonzalez3, Arshad Desai3, Andrew K Shiau4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30377272      PMCID： PMC6243232          DOI： 10.1073/pnas.1813310115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

Review 1.  Polo-like kinases: structural variations lead to multiple functions.

Authors:  Sihem Zitouni; Catarina Nabais; Swadhin Chandra Jana; Adán Guerrero; Mónica Bettencourt-Dias
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

2.  Mitotic Golgi disassembly is required for bipolar spindle formation and mitotic progression.

Authors:  Gianni Guizzunti; Joachim Seemann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

3.  Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-06       Impact factor: 11.205

4.  Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Authors:  Andrew J Holland; Don W Cleveland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

5.  Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

Authors:  Jacqueline M Mason; Dan Chi-Chia Lin; Xin Wei; Yi Che; Yi Yao; Reza Kiarash; David W Cescon; Graham C Fletcher; Donald E Awrey; Mark R Bray; Guohua Pan; Tak W Mak
Journal:  Cancer Cell       Date:  2014-07-17       Impact factor: 31.743

6.  Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.

Authors:  Yao Liang Wong; John V Anzola; Robert L Davis; Michelle Yoon; Amir Motamedi; Ashley Kroll; Chanmee P Seo; Judy E Hsia; Sun K Kim; Jennifer W Mitchell; Brian J Mitchell; Arshad Desai; Timothy C Gahman; Andrew K Shiau; Karen Oegema
Journal:  Science       Date:  2015-04-30       Impact factor: 47.728

7.  53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.

Authors:  Franz Meitinger; John V Anzola; Manuel Kaulich; Amelia Richardson; Joshua D Stender; Christopher Benner; Christopher K Glass; Steven F Dowdy; Arshad Desai; Andrew K Shiau; Karen Oegema
Journal:  J Cell Biol       Date:  2016-07-18       Impact factor: 10.539

8.  GOLPH3 drives cell migration by promoting Golgi reorientation and directional trafficking to the leading edge.

Authors:  Mengke Xing; Marshall C Peterman; Robert L Davis; Karen Oegema; Andrew K Shiau; Seth J Field
Journal:  Mol Biol Cell       Date:  2016-10-05       Impact factor: 4.138

9.  Actin- and microtubule-dependent regulation of Golgi morphology by FHDC1.

Authors:  Sarah J Copeland; Susan F Thurston; John W Copeland
Journal:  Mol Biol Cell       Date:  2015-11-12       Impact factor: 4.138

10.  Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.

Authors:  Simone Treiger Sredni; Anders W Bailey; Amreena Suri; Rintaro Hashizume; Xingyao He; Nundia Louis; Tufan Gokirmak; David R Piper; Daniel M Watterson; Tadanori Tomita
Journal:  Oncotarget       Date:  2017-11-24
  10 in total
  7 in total

1.  Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

2.  Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.

Authors:  Dominic P Byrne; Christopher J Clarke; Philip J Brownridge; Anton Kalyuzhnyy; Simon Perkins; Amy Campbell; David Mason; Andrew R Jones; Patrick A Eyers; Claire E Eyers
Journal:  Biochem J       Date:  2020-07-17       Impact factor: 3.857

3.  Role for polo-like kinase 4 in mediation of cytokinesis.

Authors:  Michael F Press; Bin Xie; Simon Davenport; Yu Zhou; Roberta Guzman; Garry P Nolan; Neil O'Brien; Michael Palazzolo; Tak W Mak; Joan S Brugge; Dennis J Slamon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 11.205

Review 4.  The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

Authors:  Andrea Ghelli Luserna di Rorà; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2019-11-26       Impact factor: 17.388

5.  TRIM37 controls cancer-specific vulnerability to PLK4 inhibition.

Authors:  Franz Meitinger; Midori Ohta; Kian-Yong Lee; Sadanori Watanabe; Robert L Davis; John V Anzola; Ruth Kabeche; David A Jenkins; Andrew K Shiau; Arshad Desai; Karen Oegema
Journal:  Nature       Date:  2020-09-09       Impact factor: 49.962

6.  Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.

Authors:  Yi Zhao; Juan Yang; Jiarui Liu; Yiqing Cai; Yang Han; Shunfeng Hu; Shuai Ren; Xiangxiang Zhou; Xin Wang
Journal:  Cell Death Dis       Date:  2021-06-23       Impact factor: 8.469

Review 7.  Keep Calm and Carry on with Extra Centrosomes.

Authors:  Batuhan Mert Kalkan; Selahattin Can Ozcan; Nicholas J Quintyne; Samantha L Reed; Ceyda Acilan
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.